Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Effective Desensitization Strategy for Patients with Sickle Cell Disease with High Donor Specific Antibodies Undergoing Haploidentical Bone Marrow Transplant with Posttransplant Cyclophosphamide

Eden Biltibo, Reena Jayani, Leena Karnik, Adam Gassas, Farah O'Boyle, Daniel Dexter, Karina Wilkerson, Katie S. Gatwood, Lindsay Orton, Bhagirathbhai Dholaria, Bipin N. Savani, Brian G. Engelhardt, Salyka M. Sengsayadeth, Carrie Lynn Kitko, James P Connelly, Adetola A. Kassim, Josu de la Fuente

Blood (2022) 140 (Supplement 1): 7613–7615.

https://doi.org/10.1182/blood-2022-162825

Published: 2022

Journal Articles

Complex Clonal Evolution Can Occur Following Transplantation for Transfusion Dependent Thalassaemia in the Context of Mixed Myeloid Chimerism and Reduced Conditioning Regimens

Adam Gassas, Farah O'Boyle, Shahzya Chaudhury, Toni Petterson, Kirstin Lund, Leena Karnik, Josu de la Fuente

Blood (2021) 138 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2021-153519

Published: 2021

Journal Articles

Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-141535

Published: 2020

Journal Articles

Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease

Dilan A Patel, MD, Josu de la Fuente, Michael Matheney, MD, Leena Karnik, FRCPath, MRCP, Heidi Chen, PhD, Katie S. Gatwood, PharmD, Kathryn A. Culos, PharmD, Karina L Wilkerson, NP, MSN, Michael T. Byrne, DO, Salyka M. Sengsayadeth, MD, Stacey Ann Goodman, MD, Bhagirathbhai Dholaria, MBBS, Bipin N. Savani, MD, Wichai Chinratanalab, MD, Reena Jayani, MD, Jim Connelly, MD, Carrie Kitko, MD, Brian G. Engelhardt, MD, Adetola A. Kassim, MDMS

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-143039

Published: 2020

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Adetola A. Kassim, MDMS, Josu de la Fuente, Ali Debsan Alahmari, MBBS, MD MNAMS, Michael J. Eckrich, MD MPH, Rabi Hanna, MD, Nathalie Dhedin, MD, Biljana N. Horn, MD, Vandy Black, MDMSc, Roseane V Gouveia, Adriana Seber, MDMS, Belinda Pinto Simões, MD PhD, Thalita Cristina de Mello Costa, MD, Renato Guerino-Cunha, Carmem M. S. Bonfim, MDPhD, Roberto Luiz da Silva, Nelson Hamerschlak, MD PhD, Juliana Folloni Fernandes, MD, Michael Kent, MDBS, Satya Prakash Yadav, MBBS, MD, Erfan Nur, MDPhD, Mohsen Alzahrani, Ben Carpenter, PhD, William Tse, MD, Maria Isabel, Hemalatha G Rangarajan, MD, Ibrahim Ahmed, MD, Adeseye Michael Akinsete, MBBS, Courtney D. Fitzhugh, MD, Kathryn A. Culos, PharmD, Leena Karnik, FRCPath, MRCP, James Connelly, MD, Carrie Kitko, MD, Jennifer Andrews, MDMSc, Karina L Wilkerson, NP, MSN, Robert Brodsky, Tatsuki Koyama, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-141771

Published: 2020

Journal Articles

Stable Neurocognitive Function with Improvement in Processing Speed Following Haploidentical Bone Marrow Transplant with Post-Transplant Cytoxan in Children and Adolescents with Sickle Cell Disease

Dilan A Patel, MD, Kemar V Prussien, Karina L Wilkerson, NP, MSN, Becky Armstrong, PhD, Leena Karnik, FRCPath, MRCP, Adetola A. Kassim, MDMS, Josu de la Fuente, FRCP, PhD FRCPath

Blood (2019) 134 (Supplement_1): 2277.

https://doi.org/10.1182/blood-2019-124769

Published: 2019

Journal Articles

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in b Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD but a High Rate of Long-Term Mixed Chimerism

Farah O'Boyle, PhD, Leena Karnik, FRCPath, MRCP, Kirstin Lund, MRCP, BSc, Richard Szydlo, PhD, Josu de la Fuente, FRCP, PhD FRCPath

Blood (2017) 130 (Supplement 1): 3323.

https://doi.org/10.1182/blood.V130.Suppl_1.3323.3323

Published: 2017

Journal Articles

Pre-Transplantation Suppression of Haemopoiesis Is Associated with a High Rate of Macrophage Activation Syndrome in Ptcy Haploidentical Transplantation for Haemoglobinopathies

Satyendra Katewa, Gaurav Kharya, Leena Karnik, FRCPath, MRCP, Adetola A. Kassim, MD MS, Josu de la Fuente, FRCP, PhD FRCPath

Blood (2017) 130 (Supplement 1): 1931.

https://doi.org/10.1182/blood.V130.Suppl_1.1931.1931

Published: 2017

Journal Articles

Experience of Endocrine Late Effects in Children with Haemolobinopathies Post Thiotepa Based Haematopoetic Stem Cell Transplant (HSCT) Regimens

Roochi Trikha, MB ChB, PhD, Catherine Hurley, Saji Alexander, Josu de la Fuente, Leena Karnik, MD FRCPath, MBBS,

Blood (2016) 128 (22): 5801.

https://doi.org/10.1182/blood.V128.22.5801.5801

Published: 2016

Journal Articles

Haploidentical Bone Marrow Transplant with Post-Transplant Cytoxan Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Multicenter Learning Collaborative

Nathalie Dhedin, MD, Josu de la Fuente, Francoise Bernaudin, MD, Mathieu Kuentz, MD, Leena Karnik, MD FRCPath, MBBS,, Tatsuki Koyama, PhD, Robert A. Brodsky, MD, Michael DeBaun, MD, Adetola A. Kassim, MD MS

Blood (2016) 128 (22): 1233.

https://doi.org/10.1182/blood.V128.22.1233.1233

Published: 2016

Journal Articles

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in β Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD

Farah O'Boyle, PhD, Leena Karnik, MD FRCPath, MBBS,, Anne Bradshaw, Richard M Szydlo, Josu de la Fuente, PhD FRCP, FRCPI, FRCPCH, FRCPath

Blood (2016) 128 (22): 1283.

https://doi.org/10.1182/blood.V128.22.1283.1283

Published: 2016

Journal Articles

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Matched and Single Antigen Mismatched Unrelated Bone Marrow Transplantation in Haemoglobinopathies Is Feasible and Leads to Early and Sustanined Engraftment with No Long-Term Toxicity or GvHD

Farah O'Boyle, PhD, Leena Karnik, MD FRCPath, MBBS,, Anne Bradshaw, Richard M Szydlo, Josu de la Fuente, PhD FRCP, FRCPI, FRCPCH, FRCPath

Blood (2016) 128 (22): 2468.

https://doi.org/10.1182/blood.V128.22.2468.2468

Published: 2016

Journal Articles

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in Haemoglobinopathies Leads to Early and Sustanined Engraftment with Low Incidence of VOD and GvHD

Farah O'Boyle, PhD, Sandra Hing, PhD, Yvonne Harrington, Subarna Chakravorty, PhD FRCPath, Leena Karnik, MD FRCPath, MBBS,, Helen New, PhDFRCPath, Anne Bradshaw, Richard Szydlo, PhD, Josu de la Fuente, PhD FRCP, FRCPI, FRCPCH, FRCPath

Blood (2015) 126 (23): 1906.

https://doi.org/10.1182/blood.V126.23.1906.1906

Published: 2015

Journal Articles

Haploidentical BMT with a Post-Infusion of Stem Cells Cyclophosphamide Approach Is Feasible and Leads to a High Rate of Donor Engraftment in Haemoglobinopathies Allowing Universal Application of Transplantation

Josu de la Fuente, PhD FRCP, FRCPI, FRCPCH, FRCPath, Farah O'Boyle, PhD, Yvonne Harrington, Anne Bradshaw, Sandra Hing, PhD, Subarna Chakravorty, PhD FRCPath, Leena Karnik, MD FRCPath, MBBS,, Helen New, PhDFRCPath, Richard Szydlo, PhD, Baba PD Inusa, MBBS, FMCPaed, FRCPCH, MRCP, DCP, Paul Telfer, FRCPath,MD

Blood (2015) 126 (23): 4317.

https://doi.org/10.1182/blood.V126.23.4317.4317

Published: 2015

Journal Articles

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads To High Rates Of Long-Term Engraftment and Low Toxicity Enabling The Use Of Mismatched and Unrelated Donors For Transplantation In Haemoglobinopathies

Josu de la Fuente, PhD, FRCP, MRCPCH, FRCPath, Farah O'Boyle, PhD, Yvonne Harrington, RCN, Nancy O'Brien, RCN, Natalie Killeen, Subarna Chakravorty, PhD, FRCPath, MRCPCH, Leena Karnik, FRCPath, Richard Szydlo, PhD, Irene Roberts, MD FRCP FRCPCH FRCPath

Blood (2013) 122 (21): 2041.

https://doi.org/10.1182/blood.V122.21.2041.2041

Published: 2013

Journal Articles

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads to Earlier Engraftment and Higher Donor Chimerism Than Busulfan/Cyclophosphamide, and Enables the Use of Mismatched and Unrelated Donors for Transplantation in Haemoglobinopathies

Farah O'Boyle, PhD, Natalie Killeen, Mikel Valganon, BSc, Subarna Chakravorty, PhD, FRCPath, MRCPCH, Leena Karnik, FRCPath, Helen New, PhD, FRCP, FRCPath, Letizia Foroni, MD, PhD, Richard Szydlo, PhD, Irene Roberts, Josu de la Fuente, PhD, FRCP, MRCPCH, FRCPath

Blood (2012) 120 (21): 3234.

https://doi.org/10.1182/blood.V120.21.3234.3234

Published: 2012

Journal Articles

Rapid Recovery of CD4 Counts Following Low Dose Alemtuzumab Conditioning During HLA Matched Related Bone Marrow Transplant for Children with Haemoglobinopathies

Lucy Cook, MRCP, FRCPath, Farah O'Boyle, MRCP, FRCPath, Leena Karnik, MRCP, FRCPath, Helen New, FRCP, FRCPath, Irene Roberts, MD, Josu de la Fuente, FRCP, FRCPath

Blood (2010) 116 (21): 2335.

https://doi.org/10.1182/blood.V116.21.2335.2335

Published: 2010

Journal Articles

Veno-Occlusive Disease After Haematopoietic Stem Cell Transplantation for β Thalassaemia Major Is Predicted by the Severity of Hepatic Fibrosis and Ameliorated by Defibrotide

Prashant Hiwarkar, Farah O'Boyle, Leena Karnik, Helen New, FRCP, FRCPath, Richard Szydlo, Irene Roberts, MD, Josu de la Fuente, FRCP, FRCPath

Blood (2010) 116 (21): 1330.

https://doi.org/10.1182/blood.V116.21.1330.1330

Published: 2010

Journal Articles

Donor Lymphocyte Infusion Is an Effective Management of Increasing Mixed Chimerism, and High Risk Disease with Minimal Side Effects.

Geothy Kochethu, Leena Karnik, Ginny Turner, Mike Griffiths, Mark Velangi, Sarah Lawson, Phil Darbyshire

Blood (2006) 108 (11): 3672.

https://doi.org/10.1182/blood.V108.11.3672.3672

Published: 2006

NARROW

Effective Desensitization Strategy for Patients with Sickle Cell Disease with High Donor Specific Antibodies Undergoing Haploidentical Bone Marrow Transplant with Posttransplant Cyclophosphamide

Complex Clonal Evolution Can Occur Following Transplantation for Transfusion Dependent Thalassaemia in the Context of Mixed Myeloid Chimerism and Reduced Conditioning Regimens

Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia

Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Stable Neurocognitive Function with Improvement in Processing Speed Following Haploidentical Bone Marrow Transplant with Post-Transplant Cytoxan in Children and Adolescents with Sickle Cell Disease

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in b Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD but a High Rate of Long-Term Mixed Chimerism

Pre-Transplantation Suppression of Haemopoiesis Is Associated with a High Rate of Macrophage Activation Syndrome in Ptcy Haploidentical Transplantation for Haemoglobinopathies

Experience of Endocrine Late Effects in Children with Haemolobinopathies Post Thiotepa Based Haematopoetic Stem Cell Transplant (HSCT) Regimens

Haploidentical Bone Marrow Transplant with Post-Transplant Cytoxan Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Multicenter Learning Collaborative

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in β Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Matched and Single Antigen Mismatched Unrelated Bone Marrow Transplantation in Haemoglobinopathies Is Feasible and Leads to Early and Sustanined Engraftment with No Long-Term Toxicity or GvHD

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in Haemoglobinopathies Leads to Early and Sustanined Engraftment with Low Incidence of VOD and GvHD

Haploidentical BMT with a Post-Infusion of Stem Cells Cyclophosphamide Approach Is Feasible and Leads to a High Rate of Donor Engraftment in Haemoglobinopathies Allowing Universal Application of Transplantation

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads To High Rates Of Long-Term Engraftment and Low Toxicity Enabling The Use Of Mismatched and Unrelated Donors For Transplantation In Haemoglobinopathies

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads to Earlier Engraftment and Higher Donor Chimerism Than Busulfan/Cyclophosphamide, and Enables the Use of Mismatched and Unrelated Donors for Transplantation in Haemoglobinopathies

Rapid Recovery of CD4 Counts Following Low Dose Alemtuzumab Conditioning During HLA Matched Related Bone Marrow Transplant for Children with Haemoglobinopathies

Veno-Occlusive Disease After Haematopoietic Stem Cell Transplantation for β Thalassaemia Major Is Predicted by the Severity of Hepatic Fibrosis and Ameliorated by Defibrotide

Donor Lymphocyte Infusion Is an Effective Management of Increasing Mixed Chimerism, and High Risk Disease with Minimal Side Effects.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only